A significant portion of the anti-tumour response induced by DMXAA was lost in IFNAR-deficient mice and Batf3−/− mice, supporting the role of cDC1s and type I IFN signalling in STING agonist activity [155]. The gene discussed is IFNAR1; the disease is neoplasm.